Thing is that if this phase 2 trial turns out to be VERY successful, IMU may not have the option of attempting to bring it to market on its own. Demand may be so great if it turns out to be more of a cure than a treatment and the option of licence manufacture would be the obvious way to go.
All of that is a best case scenario commentary of course. Let's see whare the trial leads us in six months time.
Ann: Imugene doses first patient in HER-Vaxx phase 2 trial, page-32
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.8¢ | 3.8¢ | 3.7¢ | $270.7K | 7.251M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 949810 | 3.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.8¢ | 2277658 | 11 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
